Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 304

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram

Steyerberg, E.W., Roobol, M.J., Kattan, M.W., van der Kwast, T.H., de Koning, H.J., Schröder, F.H. · 2007 · Journal of Urology

Abstract

PURPOSE: Screening with serum prostate specific antigen testing leads to the detection of many prostate cancers early in their natural history. Statistical models have been proposed to predict indolent cancer. We validated and updated model predictions for a screening setting. MATERIALS AND METHODS: We selected 247 patients with clinical stage T1C or T2A from the European Randomized Study on Screening for Prostate Cancer who were treated with radical prostatectomy. We validated a nomogram that had previously been developed in a clinical setting. Predictive characteristics were serum prostate specific antigen, ultrasound prostate volume, clinical stage, prostate biopsy Gleason grade, and total length of cancer and noncancer tissue in biopsy cores. Indolent cancer was defined as pathologically organ confined cancer 0.5 cc or less in volume without poorly differentiated elements. Logistic regression was used to update the previous model and examine the contribution of other potential predictors. RESULTS: Overall 121 of 247 patients (49%) had indolent cancer, while the average predicted probability was around 20% (p <0.001). Effects of individual variables were similar to those found before and discriminative ability was adequate (AUC 0.76). An updated model was constructed, which merely recalibrated the nomogram and did not apply additional predictors. CONCLUSIONS: Prostate cancers identified in a screening setting have a substantially higher likelihood of being indolent than those predicted by a previously proposed nomogram. However, an updated model can support patients and clinicians when the various treatment options for prostate cancer are considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.juro.2006.08.068

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 304

Metadata

Authors
Steyerberg, E. W., Roobol, M. J., Kattan, M. W., van der Kwast, T. H., de Koning, H. J., & Schröder, F. H.
Venue
Journal of Urology
Published
2007-01
Volume
177
Issue
1
Pages
107-112
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2163195821
Cited by
304
References
15
FWCI
30.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram. https://app.cochat.ai/papers/10.1016/j.juro.2006.08.068
The paper
Steyerberg, E. W., Roobol, M. J., Kattan, M. W., van der Kwast, T. H., de Koning, H. J., & Schröder, F. H. (2007). Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram. Journal of Urology. https://doi.org/10.1016/j.juro.2006.08.068

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.